The idea that pharmaceutical companies focus on treatment at the expense of cures is inaccurate. Not because they’ve decided to put the greater good ahead of profits, but because they realized they could price breakthrough cures to match the customer LTV of chronic treatments.

Novartis recently won approval for a cure to a rare genetic disorder, priced at two million dollars: https://www.reuters.com/article/us-novartis-genetherapy/nova...

I guess everything because Parkinsons is a catastrophic illness from a quality of life perspective.

(a) I have no reason to believe at this point, a priori, that Parkinson's isn't curable (Clarke's First Law)

(b) To address that issue, I vote for politicians who advocate for radically restructuring how healthcare is paid for in the US to minimize incentives to gouge unlucky individuals